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Ranolazine and the Myocardial Demand–Supply Balance*
Francis J. Klocke, MD
Chicago, IllinoisThe emergence of ranolazine as an effective antian-
ginal agent (1,2) has prompted recurring interest in
identifying mechanisms by which this agent can
favorably affect the imbalance between myocardial
oxygen demand and supply underlying anginal
episodes.
POS S I BLE INFLUENCES ON
MYOCARD IAL OXYGEN DEMAND
Early studies of ranolazine centered on reductions
in myocardial oxygen demand produced by partial
inhibition of fatty acid oxidation, particularly as free
fatty acid levels increase locally during ischemic
episodes. More recent studies report that this
mechanism is unlikely to be operative at the plasma
levels of ranolazine associated with beneficial clin-
ical effect. A reduction in myocardial oxygen de-
mand has also been questioned, because ranolazine
only minimally decreases resting and peak values of
systolic pressure and heart rate during exercise.
See page 1301
Despite the established value of the pressure-rate
product as an index of global left ventricular (LV)
oxygen consumption, it might not fully reflect other
factors known to influence myocardial metabolic
requirements (e.g., contractile state and muscle
shortening). The global index could conceivably
also fail to reflect ranolazine-induced reductions in
locally increased fatty acid oxidation during ischemia.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Feinberg Cardiovascular Research Institute and the Division of
Cardiology, Department of Medicine, Feinberg School of Medicine,
Northwestern University, Chicago, Illinois.POSS I BLE INFLUENCES ON
MYOCARD IAL OXYGEN SUPPLY
As recently reviewed by Hale et al. (3), studies
establishing that ranolazine inhibits the late sodium
current (INa) in cardiac cells have led to proposals that
it improves myocardial perfusion by attenuating dia-
stolic contractile dysfunction caused by calcium over-
load. Several laboratories have reported reductions in
myocardial necrosis and LV dysfunction in isolated
hearts and occlusion-reperfusion animal models.
However, quantitative measurements of myocardial
flow have been performed infrequently. In a rabbit
model of reperfused infarction in which ranolazine
reduced infarct size, it did not have a significant effect
on full-thickness regional flow measured with radio-
active microspheres (4).
P I LOT S INGLE - PHOTON
EMI S S ION COMPUTED
TOMOGRAPHY PERFUS ION
STUDY IN ANG INA PAT IENTS
In this issue of iJACC, Venkataraman et al. (5)
report that short-term ranolazine therapy improved
some measures of myocardial perfusion in a small
group of coronary patients with stable angina or an
anginal equivalent and reversible perfusion defects
during treadmill exercise testing. With automated
analysis of sestamibi single-photon emission com-
puted tomography images and a 17-segment LV
model, the addition of ranolazine to conventional
antianginal therapy improved summed stress and
summed difference scores systematically in the full
20-patient cohort. With automated analysis of po-
lar maps, statistically significant improvement was
also achieved in 14 patients in whom the extent and
severity of ischemia was judged to be reduced on
side-by-side visual analysis.
The authors carefully point out that this is a small
nonrandomized single center study that does not
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1311nclude a placebo control and shows considerable
nterindividual variability in degree of improve-
ent. The findings are based on measurements of
elative rather than absolute perfusion, with pat-
erns of perfusion in patients evaluated against a
ormal database.
ACTORS INFLUENC ING
LOW DI STAL TO
ORONARY STENOSES
icrovascular vasodilator reserve and extravascular
ompressive forces play pivotal roles in regulating
yocardial flow distal to a coronary artery stenosis.
lthough, ranolazine-induced reductions in dia-
tolic dysfunction are receiving increasing attention,
ts effects on microvascular resistance vessels remain
ndefined.
xtravascular compressive forces. Extravascular
ompressive forces have complex effects on imped-
nce to flow, involving important capacitive and
nertial as well as resistive factors (6). The magni-
ude of these effects varies transmurally in diastole
s well as systole, reflecting the corresponding
ifferences between intraventricular and intraperi-
ardial pressures. Systolic compression of intramyo-
ardial vessels limits coronary inflow and displaces a
ignificant fraction of intravascular blood volume
primarily antegradely but to some degree retro-
radely as well). Because of the large transmural
radient in systolic compressive forces, these effects
estrict flow particularly in the subendocardium.
he speed with which intramyocardial vessels com-
ressed during systole refill during early diastole
epends on the speed of myocardial relaxation.
erhaps more importantly, elevations in intraven-
ricular pressure (and therefore wall tension) can
estrict flow throughout diastole, again particularly
n the subendocardium. In the setting of a flow-
imiting stenosis, the shorter diastolic durations
ssociated with increasing heart rates can be another
imiting factor.
It has long been appreciated that compressive
ffects limiting subendocardial perfusion are ampli-
ed as preload increases (7,8). These effects assume
ncreasing importance during exercise, particularly
n the presence of a coronary stenosis (9). Thus, the
ossibility that ranolazine increases myocardial per-
usion by mitigating adverse effects of augmented
iastolic compressive forces clearly merits further
tudy. Quantitative measurements of ranolazine’s
ffects on transmural flows in reversibly (rather than
rreversibly) injured myocardium could be helpful in
valuating this possibility. cmerging complexities of microvascular vasodilator
eserve. The primary locus of coronary vasodilator
eserve has traditionally been thought of as a ho-
ogeneous array of resistance vessels that become
aximally dilated when myocardium becomes isch-
mic and whose caliber is influenced primarily by
etabolic factors. As recently reviewed by Duncker
nd Bache (10), several complexities relevant to
ntianginal agents have now been identified.
First, factors affecting microvessel caliber vary
mportantly with vessel size. Metabolic vasodilation
riginates primarily in arterioles 100 m in di-
meter. Conversely, 100- to 400-m arterioles are
nfluenced primarily by endothelial production of
asodilating agents such as nitric oxide. The 100- to
00-m vessels constitute a substantial fraction of
oronary resistance under basal conditions and an
ven higher fraction in ischemic areas when
100-m vessels are dilated by local metabolic
actors. The terms “endothelium-dependent” and
endothelium-independent” vasodilation are now
sed to characterize the differing responses of these
larger” and “smaller” arterioles. Increases in flow
uring exercise involve both. As flow increases in
esponse to metabolic vasodilation in smaller arte-
ioles, concomitant increases in shear stress on the
ndothelial surface of larger arterioles stimulate
ncreased production of nitric oxide and other
asodilators. When endothelium is dysfunctional,
he amount of potential vasodilation in larger arte-
ioles is reduced, causing reductions in both suben-
ocardial and full-thickness flow reserve. Interest-
ngly, Deshmukh et al. (11) have recently reported
hat ranolazine can improve endothelial function in
eripheral arterial beds in patients with stable cor-
nary disease.
Second, the inner layers of myocardium are also
upplied by specialized intramural penetrating arteries.
hese vessels vary in diameter from 100 to 500 m
nd traverse the LV wall to the subendocardium
ithout in-wall branching. Intra-arterial pressure de-
reases along their length. They too are more respon-
ive to endothelium-dependent than metabolic stim-
li. Variations in their tone can directly affect
ubendocardial flow. Nitroglycerin-induced relief of
ngina often involves their vasodilation.
Third, in the presence of a flow-limiting stenosis,
linical as well as experimental studies indicate that
oronary resistance vessels are not always dilated max-
mally in regions that become ischemic. This reflects,
t least in part, the limited sensitivity of larger arte-
ioles to metabolic factors. In addition, residual vaso-
onstrictor responses to alpha-adrenoceptor activity,
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1312latelet products, and neurohormonal factors such as
ngiotensin II and endothelin have been reported in
oth large and small arterioles. Hale et al. (3) have
oted that ranolazine has binding affinity for alpha1-
nd beta1-adrenergic receptors and serotonin
-HT1A and 5-HT2 receptors, but the significance
f these observations (if any) is unknown.
Fourth, microvascular vessel caliber also depends
mportantly on local intravascular distending pres-
ure. As reflected by curvilinear pressure-flow rela-
ionships in coronary beds that are maximally vaso-
ilated, resistance vessel diameters decrease
linearly and increasingly rapidly as intravascular
ressure falls below 60 mm Hg (12,13).
ONCLUS IONS
s emphasized by Venkataraman et al. (5), their
urrent study must be considered hypothesis-blood flow in ischemia/reperfusion in Circ Res 1979;46:6t seems to be the first such study in humans, and
he participants represent an important subset of
oronary patients. Thus, the study heightens inter-
st in possible effects of ranolazine on factors
dversely affecting coronary flow during ischemia. If
eneficial effects on extravascular compressive forces
nd/or microvascular vasodilator reserve do occur
linically, their magnitude no doubt varies among
ngina patients and might influence individual re-
ponses. Studies providing further understanding of
anolazine’s effects on pre-load and augmented
iastolic compressive forces are needed. Possible
ffects of ranolazine on larger and smaller coronary
esistance vessels, and persistent vasoconstrictor in-
uences during ischemia, also merit consideration.
eprint requests and correspondence: Dr. Francis J.
locke, 950 North Michigan Avenue, Apartment 5102,
hicago, Illinois 60611-7532. E-mail: f-klocke@generating rather than definitive. At the same time, northwestern.edu.1
1
1
1
KE F E R E N C E S
1. Chaitman BR, Pepine CJ, Parker JO,
et al. Effects of ranolazine with ateno-
lol, amlodipine, or diltiazem on exer-
cise tolerance and angina frequency in
patients with severe chronic angina. A
randomized controlled trial. JAMA
2004:291:309–16.
2. Chaitman BR, Skettino SL, Parker
JO, et al. Anti-ischemic effects and
long-term survival during ranolazine
monotherapy in patients with chronic
severe angina. J Am Coll Cardiol
2004;43:1375–82.
3. Hale SL, Shryock JC, Belardinelli L,
Sweeney M, Kloner RA. Late sodium
current inhibition as a new cardiopro-
tective approach. J Mol Cell Cardiol
2008;44:954–67.
4. Hale SL, Kloner RA. The antianginal
agent, ranolazine, reduces myocardial
infarct size but does not alter anatomic
no-reflow or regional myocardialthe rabbit. J Cardiovasc Pharmacol
Ther 2008;13:226–32.
5. Venkataraman R, Belardinelli L,
Blackburn B, Heo J, Iskandrian AE.
A study of the effects of ranolazine using
automated quantitative analysis of serial
myocardial perfusion images. J Am Coll
Cardiol Img 2009;2:1301–9.
6. Klocke FJ. Perfusion and function in
the normal and abnormal heart. In:
Germano G, Berman DS, editors.
Clinical Gated Cardiac SPECT. 2nd
edition. New York, NY: Blackwell
Publishing, 2006;1:1–25.
7. Kjekshus JK. Mechanism for flow dis-
tribution in normal and ischemic
myocardium during increased ventric-
ular preload in the dog. Circ Res
1974;33:489–99.
8. Ellis AK, Klocke FJ. Effects of preload
on the transmural distribution of per-
fusion and pressure-flow relationships
in the canine coronary vascular bed.8–77. y9. Ball RM, Bache RJ. Distribution of
myocardial blood flow in the exercis-
ing dog with restricted coronary artery
inflow. Circ Res 1976;38:60–6.
0. Duncker DJ, Bache RJ. Regulation of
coronary blood flow during exercise.
Physiol Rev 2008;88:1009–86.
1. Deshmukh SH, Patel SR, Pinassi E,
et al. Ranolazine improves endothelial
function in patients with stable coro-
nary artery disease. Coron Artery Dis
2009;20:343–7.
2. Klocke FJ, Mates RE, Canty JM Jr.,
Ellis AK. Coronary pressure-flow re-
lationships. Controversial issues and
probable implications. Circ Res 1985;
56:310–23.
3. Spaan JA, Piek JJ, Hoffman JI, Siebes
M. Physiological basis of clinically
used coronary hemodynamic indices.
Circulation 2006;113:446–55.
ey Words: antianginal effects
ranolazine.
